MANNKIND CORP Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent
MANNKIND CORP (MNKD) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent of 45.00% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2026-02-26
- MANNKIND CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2025 was 45.00%.
- MANNKIND CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2024 was 0.00%.
- MANNKIND CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2023 was -5.60%, a 1500.00% decline from fiscal 2022.
- MANNKIND CORP effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, percent for fiscal 2022 was 0.40%, a 33.33% increase from fiscal 2021.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Percent 12 month |
|---|---|
| 2025-12-31 | 45.00% 10-K · filed 2026-02-26 |
| 2024-12-31 | 0.00% 10-K · filed 2026-02-26 |
| 2023-12-31 | -5.60% 10-K · filed 2026-02-26 |
| 2022-12-31 | 0.40% 10-K · filed 2025-02-26 |
| 2021-12-31 | 0.30% 10-K · filed 2024-02-27 |
| 2020-12-31 | -0.50% 10-K · filed 2023-02-23 |
| 2019-12-31 | -0.90% 10-K · filed 2021-02-25 |
| 2018-12-31 | -6.50% 10-K · filed 2020-02-25 |
| 2017-12-31 | -5.00% 10-K · filed 2019-02-26 |
| 2016-12-31 | 0.00% 10-K · filed 2019-02-26 |
| 2015-12-31 | 0.00% 10-K · filed 2018-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |